FullScopeMD
US$ 29.93
weight loss glp-1 agonists What Are For Loss? Frontiers | GLP−1 receptor agonists
Description
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
At present, tirzepatide is the leading GLP-1/GIP dual agonist and has been approved for marketing in many countries, including the US, Europe and Japan, for the treatment of T2D
Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
LA received speaking and consulting fees from Pfizer, Boehringer Ingelheim, and Roche for work unrelated to this study
